Investigators may apply from accredited academic medical centers, research institutions or universities in the US, US territories, Canada and the United Kingdom. Applications must be written in English. The sponsoring institution must ensure the necessary facilities and infrastructure are in place to execute the planned research project. The institution must also accept the award conditions, including the Budget Use of Funds and provide governance over fund expenditures.
Sponsoring institutions must safeguard the rights and welfare of individuals who participate as subjects in research activities. In the US, the proposed activities must be reviewed through an Institutional Review Board as specified by the US Department of Health and Human Services Office for Human Research Protections, HHS OHRP. In Canada, the rights and welfare of participants are to be safeguarded through adherence to the policies and regulations of the Interagency Advisory Panel on Research Ethics / Le Groupe en Ethique de la Recherche, as well as any additional provincial regulations as applicable. Clinical protocols must be approved by an appropriately convened Research Ethics Board (REB). Proof of ACC and/or REB approvals are not required at the time of submission, but must be provided as part of the formal Grant Agreement by selected grantees.
The grantee’s institution must assure appropriate compliance of animal studies. In the U.S., IRB approval and IACUC numbers are not required at the time of application, but must be provided for final signature of the Grant Agreement, which will be sent to the grantees shortly after they have been selected. In Canada, for animal studies, all work must adhere to the standards of the Canadian Council on Animal Care / Conseil Canadien De Protection Des Animaux with protocols approved by an appropriately convened Animal Care Committee (ACC).
Sponsoring institutions must adhere to current guidelines regarding financial conflict of interest, recombinant DNA and research misconduct.
Members of Harrington Discovery Institute's review panel and Scientific Advisory Board are required to complete mutual Confidentiality & Disclosure Agreements with the Harrington Discovery Institute.
Non-public applicant information is always kept confidential (and limited in distribution to the reviewers and Harrington Discovery Institute administrative team). For those selected as Harrington Scholars, and with the applicant’s approval, the abstract summary may be used by Harrington Discovery Institute for publicity and marketing purposes (on the Harrington Discovery Institute website, news releases, etc.). A Harrington Scholar’s name, institutional affiliation and award name/year may be used at Harrington Discovery Institute’s sole discretion.
Applicants acknowledge that University Hospitals Health System may conduct research that is related to, or competitive with, proposals submitted by applicants, but University Hospitals Health System commits not to use information submitted by applications in connection with research.
The review panel consists of academic science subject matter experts and industry science professionals with experience in the applicant’s area of research.
Projects will be assessed based on:
Applicants who fail to fill out their applications by the deadline and/or in accordance with the detailed instructions are subject to disqualification at the outset of the review period or any time during the review period.
Pending how far an applicant makes it in the review process, Harrington Discovery Institute may be able to provide reviewers' comments or feedback to help applicants strengthen the proposal for future submission.
Part of Harrington Discovery Institute’s mission is to build a broad connected community of physician-scientist-innovators. Harrington Discovery Institute will hold an annual symposium that awardees are required to attend during their term.
The Harrington Scientific Symposium, held in May in Cleveland, Ohio, brings together drug development experts, national disease foundation leadership, and international leaders in medicine and Harrington Scholars. Awardees are expected to present their project and findings-to-date at least once during their term. A stipend for travel and lodging will be provided by Harrington Discovery Institute, subject to the terms of the Award Agreement.
Grant funds are provided by the Alzheimer's Drug Discovery Foundation. Allowable and unallowable costs are as follows.
Harrington Discovery Institute does not claim any rights whatsoever to patents, copyrights or trademarks to intellectual property (IP) created as a result of work sponsored by a Harrington grant.
Yearly renewal of the award is dependent on timely submission of a written progress report, as well as attendance at Harrington Discovery Institute’s Scientific Symposium.
A significant change in the project scope or work should be discussed with Harrington Discovery Institute’s Vice President of Therapeutics Development.
Awards may be transferred to another institution that agrees to assume the Policies, Terms & Conditions of the agreement. Permission to transfer the award to another institution must be obtained from Harrington Discovery Institute’s Vice President of Therapeutics Development.
Awards are managed by Harrington Discovery Institute. Harrington Discovery Institute staff will assure compliance with program policies and will be responsible for all administrative matters.
The Principal Investigator and his/her/their institution are solely responsible for execution of the project, including compliance with all relevant Federal and State laws and guidelines.
Harrington Discovery Institute reserves the right to refine and amend policies as required.
Any questions should be directed here.